Skip to content

Screening Volunteers for Clinical Trials

VRC 500: Screening Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01375530
Enrollment
4000
Registered
2011-06-17
Start date
2011-08-16
Completion date
Unknown
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Screening

Keywords

Prevention, Vaccine, Immunity, Evaluate, Screen

Brief summary

Background: \- The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health needs healthy volunteers for vaccine clinical trials. This is a screening study that is used to identify healthy volunteers who may be eligible to participate in other clinical trials at the Vaccine Research Center that evaluate investigational vaccines, monoclonal antibodies, and injection devices. The VRC conducts studies that will allow researchers to better understand the immune system and how vaccines and monoclonal antibodies work. Objectives: \- To screen healthy volunteers for clinical trials at the NIAID VRC. Eligibility: \- Healthy people between 18 and 60 years of age. They must be available to take part in clinical trials and be able to provide blood for research studies. Design: * Screening for healthy volunteers to participate in clinical trials is an ongoing process. * Volunteers will be asked about their medical history, including sexual activity and drug use, and a detailed physical exam will be performed. * Blood and urine samples may be collected, and possibly other tests as needed to evaluate the volunteer's health status. * Volunteers will not receive any investigational product in this screening protocol.

Detailed description

The purpose of this study is to recruit and screen potential study subjects, mostly healthy volunteers, to determine if they are eligible for clinical trials of investigational products. This screening study also aims to characterize and analyze demographic information as well as laboratory and other medical findings in terms of how they may affect the eligibility of subjects for specific early phase clinical trials. All work will be conducted by the VRC Clinic of the National Institutes of Health or other IRB-approved sites that are collaborating with NIAID/VRC. Educational and recruitment materials on the investigational products and protocols will be reviewed with and provided to subjects during participation in the screening protocol.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* INCLUSION CRITERIA: Age: 18 years of age or older Able and willing to complete the informed consent process Agree to have blood and/or tissue samples collected and stored for future studies of investigational products, the immune system, and/or other medical conditions

Exclusion criteria

A condition in which repeated blood draws or injections pose more than minimal risk for the subject such as hemophilia, other severe coagulation disorders or significantly impaired venous access A condition that requires active medical intervention or monitoring to avert serious danger to the participant s health or well-being Known to be pregnant or breast-feeding

Design outcomes

Primary

MeasureTime frameDescription
To screen subjects for their eligibility to participate in clinical trials.OngoingDuration of subject participation is variable, and may last from a few weeks to several months for each subject.

Countries

United States

Contacts

CONTACTVRC Recruitment
vrcrecruitment@mail.nih.gov(866) 833-5433
PRINCIPAL_INVESTIGATORLasonji A Holman, C.R.N.P.

National Institute of Allergy and Infectious Diseases (NIAID)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026